Review



murine αpd1 (mudx400  (Merck & Co)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    Merck & Co murine αpd1 (mudx400
    (A) UMAP of scRNA-seq analysis of 22,635 cells isolated from KPF CAF-HIF2 WT tumors (10,703 cells; n = 3 mice) and KPF CAF-HIF2 KO tumors (11,932 cells; n = 3 mice). Cell types were identified through graph-based clustering followed by manual annotation using marker genes. (B) Percentage of myeloid cells in each tumor. (C) M2-polarized TAMs were identified within the myeloid cell population via expression of Arg1 and Mrc1. (D) Immunosuppressive TAMs were identified within the myeloid cell population via expression of Cd274 ( Pdl1 ) and Cd86 ( B7-2 ). (E) Violin plots showing findings on scRNA-seq analysis of Ctla4 in KPF CAF-HIF2 WT and KO tumors in all identified cell types. (F) Left: Representative IHC images of CAF-HIF2 WT and KO tumors stained for FoxP3 (n = 5-6/group); scale bars, 50 µm. Right: Quantification of FoxP3+ Tregs per field. (G) Schematic for administration of PT2399 + αCTLA4 in a syngeneic flank KPC model. i.p., intraperitoneal; o.g., oral gavage; b.i.d., bid in die (twice a day). (H) Tumor growth curve from (A) (n = 10/group). Veh, vehicle; P , by Mann–Whitney U test. (I) Schematic for administration of PT2399 + <t>αCTLA4/αPD1</t> in a syngeneic orthotopic KPC model. (J) Kaplan-Meier curves showing percentage survival for (C) (n = 10/group); P , by log-rank test. All error bars represent mean ± SEM; P , by Student’s t test unless otherwise noted. See also Supplementary Figure 6 and Supplementary Table 2.
    Murine αpd1 (Mudx400, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/murine αpd1 (mudx400/product/Merck & Co
    Average 90 stars, based on 1 article reviews
    murine αpd1 (mudx400 - by Bioz Stars, 2026-02
    90/100 stars

    Images

    1) Product Images from "Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment"

    Article Title: Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment

    Journal: bioRxiv

    doi: 10.1101/2021.05.21.445190

    (A) UMAP of scRNA-seq analysis of 22,635 cells isolated from KPF CAF-HIF2 WT tumors (10,703 cells; n = 3 mice) and KPF CAF-HIF2 KO tumors (11,932 cells; n = 3 mice). Cell types were identified through graph-based clustering followed by manual annotation using marker genes. (B) Percentage of myeloid cells in each tumor. (C) M2-polarized TAMs were identified within the myeloid cell population via expression of Arg1 and Mrc1. (D) Immunosuppressive TAMs were identified within the myeloid cell population via expression of Cd274 ( Pdl1 ) and Cd86 ( B7-2 ). (E) Violin plots showing findings on scRNA-seq analysis of Ctla4 in KPF CAF-HIF2 WT and KO tumors in all identified cell types. (F) Left: Representative IHC images of CAF-HIF2 WT and KO tumors stained for FoxP3 (n = 5-6/group); scale bars, 50 µm. Right: Quantification of FoxP3+ Tregs per field. (G) Schematic for administration of PT2399 + αCTLA4 in a syngeneic flank KPC model. i.p., intraperitoneal; o.g., oral gavage; b.i.d., bid in die (twice a day). (H) Tumor growth curve from (A) (n = 10/group). Veh, vehicle; P , by Mann–Whitney U test. (I) Schematic for administration of PT2399 + αCTLA4/αPD1 in a syngeneic orthotopic KPC model. (J) Kaplan-Meier curves showing percentage survival for (C) (n = 10/group); P , by log-rank test. All error bars represent mean ± SEM; P , by Student’s t test unless otherwise noted. See also Supplementary Figure 6 and Supplementary Table 2.
    Figure Legend Snippet: (A) UMAP of scRNA-seq analysis of 22,635 cells isolated from KPF CAF-HIF2 WT tumors (10,703 cells; n = 3 mice) and KPF CAF-HIF2 KO tumors (11,932 cells; n = 3 mice). Cell types were identified through graph-based clustering followed by manual annotation using marker genes. (B) Percentage of myeloid cells in each tumor. (C) M2-polarized TAMs were identified within the myeloid cell population via expression of Arg1 and Mrc1. (D) Immunosuppressive TAMs were identified within the myeloid cell population via expression of Cd274 ( Pdl1 ) and Cd86 ( B7-2 ). (E) Violin plots showing findings on scRNA-seq analysis of Ctla4 in KPF CAF-HIF2 WT and KO tumors in all identified cell types. (F) Left: Representative IHC images of CAF-HIF2 WT and KO tumors stained for FoxP3 (n = 5-6/group); scale bars, 50 µm. Right: Quantification of FoxP3+ Tregs per field. (G) Schematic for administration of PT2399 + αCTLA4 in a syngeneic flank KPC model. i.p., intraperitoneal; o.g., oral gavage; b.i.d., bid in die (twice a day). (H) Tumor growth curve from (A) (n = 10/group). Veh, vehicle; P , by Mann–Whitney U test. (I) Schematic for administration of PT2399 + αCTLA4/αPD1 in a syngeneic orthotopic KPC model. (J) Kaplan-Meier curves showing percentage survival for (C) (n = 10/group); P , by log-rank test. All error bars represent mean ± SEM; P , by Student’s t test unless otherwise noted. See also Supplementary Figure 6 and Supplementary Table 2.

    Techniques Used: Isolation, Marker, Expressing, Staining, MANN-WHITNEY



    Similar Products

    murine αpd1 (mudx400  (Merck & Co)
    90
    Merck & Co murine αpd1 (mudx400
    (A) UMAP of scRNA-seq analysis of 22,635 cells isolated from KPF CAF-HIF2 WT tumors (10,703 cells; n = 3 mice) and KPF CAF-HIF2 KO tumors (11,932 cells; n = 3 mice). Cell types were identified through graph-based clustering followed by manual annotation using marker genes. (B) Percentage of myeloid cells in each tumor. (C) M2-polarized TAMs were identified within the myeloid cell population via expression of Arg1 and Mrc1. (D) Immunosuppressive TAMs were identified within the myeloid cell population via expression of Cd274 ( Pdl1 ) and Cd86 ( B7-2 ). (E) Violin plots showing findings on scRNA-seq analysis of Ctla4 in KPF CAF-HIF2 WT and KO tumors in all identified cell types. (F) Left: Representative IHC images of CAF-HIF2 WT and KO tumors stained for FoxP3 (n = 5-6/group); scale bars, 50 µm. Right: Quantification of FoxP3+ Tregs per field. (G) Schematic for administration of PT2399 + αCTLA4 in a syngeneic flank KPC model. i.p., intraperitoneal; o.g., oral gavage; b.i.d., bid in die (twice a day). (H) Tumor growth curve from (A) (n = 10/group). Veh, vehicle; P , by Mann–Whitney U test. (I) Schematic for administration of PT2399 + <t>αCTLA4/αPD1</t> in a syngeneic orthotopic KPC model. (J) Kaplan-Meier curves showing percentage survival for (C) (n = 10/group); P , by log-rank test. All error bars represent mean ± SEM; P , by Student’s t test unless otherwise noted. See also Supplementary Figure 6 and Supplementary Table 2.
    Murine αpd1 (Mudx400, supplied by Merck & Co, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/result/murine αpd1 (mudx400/product/Merck & Co
    Average 90 stars, based on 1 article reviews
    murine αpd1 (mudx400 - by Bioz Stars, 2026-02
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    (A) UMAP of scRNA-seq analysis of 22,635 cells isolated from KPF CAF-HIF2 WT tumors (10,703 cells; n = 3 mice) and KPF CAF-HIF2 KO tumors (11,932 cells; n = 3 mice). Cell types were identified through graph-based clustering followed by manual annotation using marker genes. (B) Percentage of myeloid cells in each tumor. (C) M2-polarized TAMs were identified within the myeloid cell population via expression of Arg1 and Mrc1. (D) Immunosuppressive TAMs were identified within the myeloid cell population via expression of Cd274 ( Pdl1 ) and Cd86 ( B7-2 ). (E) Violin plots showing findings on scRNA-seq analysis of Ctla4 in KPF CAF-HIF2 WT and KO tumors in all identified cell types. (F) Left: Representative IHC images of CAF-HIF2 WT and KO tumors stained for FoxP3 (n = 5-6/group); scale bars, 50 µm. Right: Quantification of FoxP3+ Tregs per field. (G) Schematic for administration of PT2399 + αCTLA4 in a syngeneic flank KPC model. i.p., intraperitoneal; o.g., oral gavage; b.i.d., bid in die (twice a day). (H) Tumor growth curve from (A) (n = 10/group). Veh, vehicle; P , by Mann–Whitney U test. (I) Schematic for administration of PT2399 + αCTLA4/αPD1 in a syngeneic orthotopic KPC model. (J) Kaplan-Meier curves showing percentage survival for (C) (n = 10/group); P , by log-rank test. All error bars represent mean ± SEM; P , by Student’s t test unless otherwise noted. See also Supplementary Figure 6 and Supplementary Table 2.

    Journal: bioRxiv

    Article Title: Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment

    doi: 10.1101/2021.05.21.445190

    Figure Lengend Snippet: (A) UMAP of scRNA-seq analysis of 22,635 cells isolated from KPF CAF-HIF2 WT tumors (10,703 cells; n = 3 mice) and KPF CAF-HIF2 KO tumors (11,932 cells; n = 3 mice). Cell types were identified through graph-based clustering followed by manual annotation using marker genes. (B) Percentage of myeloid cells in each tumor. (C) M2-polarized TAMs were identified within the myeloid cell population via expression of Arg1 and Mrc1. (D) Immunosuppressive TAMs were identified within the myeloid cell population via expression of Cd274 ( Pdl1 ) and Cd86 ( B7-2 ). (E) Violin plots showing findings on scRNA-seq analysis of Ctla4 in KPF CAF-HIF2 WT and KO tumors in all identified cell types. (F) Left: Representative IHC images of CAF-HIF2 WT and KO tumors stained for FoxP3 (n = 5-6/group); scale bars, 50 µm. Right: Quantification of FoxP3+ Tregs per field. (G) Schematic for administration of PT2399 + αCTLA4 in a syngeneic flank KPC model. i.p., intraperitoneal; o.g., oral gavage; b.i.d., bid in die (twice a day). (H) Tumor growth curve from (A) (n = 10/group). Veh, vehicle; P , by Mann–Whitney U test. (I) Schematic for administration of PT2399 + αCTLA4/αPD1 in a syngeneic orthotopic KPC model. (J) Kaplan-Meier curves showing percentage survival for (C) (n = 10/group); P , by log-rank test. All error bars represent mean ± SEM; P , by Student’s t test unless otherwise noted. See also Supplementary Figure 6 and Supplementary Table 2.

    Article Snippet: After 2 weeks of recovery, murine αCTLA4 (clone 9D9, Merck) and murine αPD1 (muDX400, Merck) or isotype control were administered IP every 4 days at 20 μg/mouse, 200 μg/mouse, and 220 μg/mouse, respectively for 2 weeks.

    Techniques: Isolation, Marker, Expressing, Staining, MANN-WHITNEY